All In Biotech

Drug Trial Radar · NCT06481085

To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

A Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of HDM1002 Tablets in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin or Diet and Exercise

Last checked: Nov 19, 2026Latest source record: Jul 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 324 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

324

Actual

Start

Jun 27, 2024

Primary completion

May 30, 2025

Study completion Jun 30, 2025

Sponsor

Sponsor type
Industry
First posted
Jul 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo controlled, parallel group study, which aims to provide data on efficacy, safety and pharmacokinetics (PK) of multiple dose levels of HDM1002 tablets in adults with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and/or diet and exercise.

Conditions

  • Type 2 Diabetes

Interventions

  • HDM1002 50 mgDrug

    HDM1002 tablets, 50 mg once daily, 12 weeks

  • HDM1002 100 mgDrug

    HDM1002 tablets, 100 mg once daily, 12 weeks

  • HDM1002 200 mgDrug

    HDM1002 tablets, 200 mg once daily, 12 weeks

  • HDM1002 400 mgDrug

    HDM1002 tablets, 400 mg once daily, 12 weeks

  • HDM1002 200 mg BIDDrug

    HDM1002 tablets, 200 mg twice daily, 12 weeks

  • PlaceboDrug

    Matching placebo will be provided

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in HbA1c at Week 12Time frame: Baseline, Week 12

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chaoyang Hospital Affiliated to Capital Medical University

    Beijing, China

  • Peking University Shougang Hospital

    Beijing, China

  • Cangzhou Central Hospital

    Cangzhou, China

  • The Second Hospital of Jilin University

    Changchun, China

  • The Fourth Hospital of Changsha City

    Changsha, China

  • The Third Hospital of Changsha City

    Changsha, China

  • Chengdu Second People's Hospital

    Chengdu, China

  • The Affiliated Hospital of Chengdu University

    Chengdu, China

  • Three Gorges Hospital Affiliated to Chongqing University

    Chongqing, China

  • The First Hospital of Handan City

    Handan, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, China

  • The Fourth Affiliated Hospital of Harbin Medical University

    Harbin, China

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, China

  • Huizhou Central People's Hospital

    Huizhou, China

  • Huzhou Central Hospital

    Huzhou, China

  • Jinan Central Hospital

    Jinan, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, China

  • The Third People's Hospital of Luoyang City

    Luoyang, China

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, China

  • The First Affiliated Hospital of Nanyang Medical College

    Nanyang, China

  • The First People's Hospital of Nanyang City

    Nanyang, China

  • Panjin Liaohe Oilfield General Hospital

    Panjin, China

  • The First Hospital of Qinhuangdao City

    Qinhuangdao, China

  • Suzhou Municipal Hospital

    Suzhou, China

  • The First Hospital of Shanxi Medical University

    Taiyuan, China

  • Tonghua Central Hospital

    Tonghua, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, China

  • Xuzhou Cancer Hospital

    Xuzhou, China

  • Yueyang People's Hospital

    Yueyang, China

  • The Second Affiliated Hospital of Zhengzhou University

    Zhengzhou, China

  • The Chinese People's Liberation Army General Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.